A Study in Patients With Amyotrophic Lateral Sclerosis (ALS)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

373

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 31, 2014

Study Completion Date

July 31, 2014

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
DRUG

E0302 (mecobalamin)

Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.

DRUG

E0302 (mecobalamin)

Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.

DRUG

Placebo

Intramuscular injection, placebo twice a week for 3.5 years.

Trial Locations (44)

Unknown

Nagoya

Akita

Aomori

Chiba

Touon-shi

Fukuoka

Kitakyusyu-shi

Fukushima

Maebashi

Higashihiroshima-shi

Miyoshi-shi

Otake-shi

Sapporo

Kanazawa

Ichinoseki-shi

Sagamihara-shi

Yokohama

Nangoku-shi

Kyoto

Tsu

Sendai

Watari-gun

Nagano

Higashisonogi-gun

Kashiwazaki-shi

Niigata

Tsukubo-gun

Ginowan-shi

Toyonaka-shi

Hasuda-shi

Saitama-shi

Ōtsu

Hamamatsu

Shizuoka

Shimotsuke-shi

Tokushima

Yoshinogawa-shi

Bunkyo-ku

Kodaira-shi

Ōta-ku

Wakayama

Yonezawa-shi

Shimonoseki-shi

Yanai-shi

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT00444613 - A Study in Patients With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter